Wanbury Limited (WANBURY) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE107F01022
Key metrics
- Market Cap
- ₹860 Cr
- P/E Ratio
- 15.01
- EPS
- 16.38
- Book Value
- 41.34
- P/B Ratio
- 5.95
- ROE
- 45.78%
- ROCE
- 25.07%
- Debt / Equity
- 1.55
- Net Margin
- 10.17%
- Revenue Growth
- 8.47%
- Profit Growth
- 116.62%
- Dividend Yield
- —
- 52W High
- ₹358.85
- 52W Low
- ₹161.50
- Market Cap Band
- small cap
- Face Value
- —
Ratios computed from the annual results period ending 2026-03-31.
About Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
- Headquarters
- Navi Mumbai, India
- Promoter Holding
- 51.31%
The full Wanbury Limited analysis
Create a free account to open the complete WANBURY deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.